More than 85% of oncology healthcare professionals say that they need to be able to explain clinical use of artificial intelligence (AI) to their patients, but less than half report being familiar with AI in health care or receiving education on the technology, researchers reported in JAMA Network Open. In response, the National Cancer Institute’s (NCI’s) Center for Biomedical Informatics and Information Technology created a top-5 tip sheet for clinicians and researchers to use when evaluating AI tools for health care.

Of the more than 20 million new cancer cases diagnosed globally in 2022, nearly half occurred in Asia—where an even higher majority of the 9.7 million deaths were also reported, according to the International Agency for Research on Cancer and American Cancer Society’s April 2024 estimates.

On June 21, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati^®) plus cetuximab for adults with KRAS G12C-variant locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

By representing perspectives from the entire cancer care team, collaboration with interprofessional colleagues is one way for oncology nurses to influence the delivery of high-quality patient care.

Confounding researchers and clinicians alike, colorectal cancer rates are dramatically increasing among younger populations. In the latest study results published in Gastroentrology, researchers quantified the drastic shift of colorectal cancer diagnoses in various young groups aged 10–24 years.

The journey from cancer diagnosis to treatment with hematopoietic stem cell transplantation (HSCT) is a complex, costly, and multifaceted process influenced by various factors that shape the course of patient care. HSCT is particularly susceptible to racial, socioeconomic, and geographic disparities in access and outcomes, given its specialized nature and limited availability in just about 200 U.S. cancer centers.

On June 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda^®) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.

Medicine marked a major milestone in April 2024, the U.S. Food and Drug Administration (FDA) said, when the agency announced it had approved its 50th biosimilar medication. Trastuzumab-strf, a biosimilar to the antineoplastic trastuzumab, had the honor of being the agency's 50th approval.

Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer—although it is 40 times rarer than melanoma, it is 3–5 times more lethal. Approximately 3,000 new cases of Merkel cell carcinoma are diagnosed every year in the United States, but its incidence is increasing because of enhanced diagnostic techniques and the prevalence of risk factors.

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto^®) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.